1. A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells

   • Juan A. Marchal
   • María C. Núñez
   • Joaquín M. Campos

   Preclinical Study 24 November 2006 Pages: 237 - 246

   

2. JNK pathway regulates estradiol-induced apoptosis in hormone-dependent human breast cancer cells

   • Nedret Altiok
   • Meral Koyuturk
   • Soner Altiok

   Preclinical Study 23 December 2006 Pages: 247 - 254

   

3. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer

   • Hilmi Ozcelik
   • Dushanthi Pinnaduwage
   • Irene L. Andrulis

   Preclinical Study 13 January 2007 Pages: 255 - 265

   

4. BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses

   • Antonio Russo
   • Valentina Calò
   • Viviana Bazan

   Preclinical study 13 January 2007 Pages: 267 - 276

   

5. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells

   • Yunfei Zhang
   • Baoan Ma
   • Qingyu Fan

   Preclinical Study 23 December 2006 Pages: 277 - 286

   

6. N-cadherin engagement provides a dominant stop signal for the migration of MDA-MB-468 breast carcinoma cells

   • S. Potthoff
   • F. Entschladen
   • K. Lang

   Preclinical Study 14 December 2006 Pages: 287 - 295

   

7. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells

   • Leslie Hodges-Gallagher
   • Cathleen D. Valentine
   • Peter J. Kushner

   Preclinical Study 21 December 2006 Pages: 297 - 309

   

8. The T393C polymorphism in the gene GNAS1 of G protein is associated with survival of patients with invasive breast carcinoma

   • Friedrich Otterbach
   • Rainer Callies
   • Kurt W. Schmid

   Preclinical Study 21 December 2006 Pages: 311 - 317

   

9. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro

   • Richard S. Finn
   • Judy Dering
   • Dennis J. Slamon

   Preclinical Study Open access 01 February 2007 Pages: 319 - 326

   

10. ESR1, AR, body size, and breast cancer risk in Hispanic and non-Hispanic white women living in the Southwestern United States

    • Martha L. Slattery
    • Carol Sweeney
    • Tim Byers

    Epidemiology 23 December 2006 Pages: 327 - 335

11. Serum prolactin levels are positively associated with mammographic density in postmenopausal women

    • Gail A. Greendale
    • Mei-Hua Huang
    • Arun Karlamangla

    Epidemiology 27 January 2007 Pages: 337 - 346

    

12. Survival after bilateral breast cancer: results from a population-based study

    • Helena M. Verkooijen
    • Vanessa Chatelain
    • Pierre O. Chappuis

    Epidemiology 21 December 2006 Pages: 347 - 357

    

13. Leukemia following breast cancer: an international population-based study of 376,825 women

    • Regan A. Howard
    • Ethel S. Gilbert
    • Lois B. Travis

    Epidemiology 13 January 2007 Pages: 359 - 368

    

14. Impact of a programme of mass mammography screening for breast cancer on socio-economic variation in survival: a population-based study

    • W. J. Louwman
    • L. V. van de Poll-Franse
    • J. W. W. Coebergh

    Epidemiology Open access 09 January 2007 Pages: 369 - 375

    

15. Mutation analysis of five candidate genes in familial breast cancer

    • Anna Marsh
    • Sue Healey
    • Georgia Chenevix-Trench

    Original Article 23 December 2006 Pages: 377 - 389